Cantor Fitzgerald Healthcare News

This is selected healthcare news for Cantor Fitzgerald, which is filed under Capital Firms. There are 17.5K news items for this page. Cantor Fitzgerald is occasionally combined with Sarepta Therapeutics, Novavax and Inovio in news items.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
9/24/2022 Portage Biotech's (PRTG) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Portage Biotech ( NASDAQ:PRTG ‚Ai Get Rating ) in a research note released on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Portage Biotech's FY2023 earnings at ($1.16) EPS. Other equities analysts also recently issued reports about the stock. Oppenheimer ...
defenseworld.net
9/24/2022 Portage Biotech's (PRTG) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Portage Biotech (NASDAQ:PRTG ‚Ai Get Rating) in a report issued on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Portage Biotech's FY2023 earnings at ($1.16) EPS. A number of other equities research analysts also recently weighed in on ...
etfdailynews.com
9/23/2022 Portage Biotech (NASDAQ:PRTG) Receives Overweight Rating from Cantor Fitzgerald - Ticker Report
Portage Biotech ( NASDAQ:PRTG ‚Ai Get Rating ) ‚Aos stock had its ‚Auoverweight‚Au rating restated by Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Portage Biotech's FY2023 earnings at ($1.16) EPS. PRTG has been the subject ...
Ticker Report
9/23/2022 Portage Biotech (NASDAQ:PRTG) Receives Overweight Rating from Cantor Fitzgerald - American Banking News
Portage Biotech ( NASDAQ:PRTG ‚Ai Get Rating ) ‚Aos stock had its ‚Auoverweight‚Au rating restated by Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Portage Biotech's FY2023 earnings at ($1.16) EPS. PRTG has been the subject ...
American Banking News
9/23/2022 Portage Biotech's (PRTG) “Overweight” Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Portage Biotech (NASDAQ:PRTG ‚Ai Get Rating) in a research report sent to investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Portage Biotech's FY2023 earnings at ($1.16) EPS. A number of other equities analysts also recently weighed ...
zolmax.com
9/23/2022 Portage Biotech's (PRTG) “Overweight” Rating Reaffirmed at Cantor Fitzgerald baseballnewssource.com
9/23/2022 Cantor Fitzgerald Weighs in on Portage Biotech Inc.'s FY2023 Earnings (NASDAQ:PRTG) - Ticker Report Ticker Report
9/23/2022 Cantor Fitzgerald Weighs in on Portage Biotech Inc.'s FY2023 Earnings (NASDAQ:PRTG) baseballnewssource.com
9/23/2022 Portage Biotech (NASDAQ:PRTG) Rating Reiterated by Cantor Fitzgerald baseballnewssource.com
9/23/2022 Portage Biotech (NASDAQ:PRTG) Rating Reiterated by Cantor Fitzgerald zolmax.com
9/23/2022 Aptose Biosciences’ (APTO) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Ticker Report Ticker Report
9/23/2022 Aptose Biosciences’ (APS) Overweight Rating Reaffirmed at Cantor Fitzgerald zolmax.com
9/23/2022 Aptose Biosciences’ (APS) Overweight Rating Reaffirmed at Cantor Fitzgerald baseballnewssource.com
9/23/2022 Corvus Pharmaceuticals’ (CRVS) Overweight Rating Reiterated at Cantor Fitzgerald zolmax.com
9/23/2022 Aptose Biosciences Inc. to Post FY2022 Earnings of ($0.60) Per Share, Cantor Fitzgerald Forecasts (TSE:APS) zolmax.com
9/23/2022 Aptose Biosciences’ (APTO) “Overweight” Rating Reaffirmed at Cantor Fitzgerald American Banking News
9/23/2022 Corvus Pharmaceuticals’ (CRVS) Overweight Rating Reiterated at Cantor Fitzgerald baseballnewssource.com
9/23/2022 Aptose Biosciences (TSE:APS) Receives “Overweight” Rating from Cantor Fitzgerald - Ticker Report Ticker Report
9/23/2022 Corvus Pharmaceuticals (NASDAQ:CRVS) Receives Overweight Rating from Cantor Fitzgerald - Ticker Report Ticker Report
9/23/2022 Cantor Fitzgerald Reiterates Overweight Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - Watch List News watchlistnews.com
9/22/2022 Gracell Biotechnologies (NASDAQ:GRCL) Receives New Coverage from Analysts at Citigroup zolmax.com
9/22/2022 Gracell Biotechnologies (NASDAQ:GRCL) Receives New Coverage from Analysts at Citigroup baseballnewssource.com
9/22/2022 PDS Biotech to Participate at Cantor Fitzgerald's Oncology Globe Newswire
9/22/2022 PDS Biotech to Participate at Cantor Fitzgerald's Oncology & HemOnc Conference | Insider Tracking insidertracking.com
9/22/2022 PDS Biotech to Participate at Cantor Fitzgerald's Oncology & HemOnc Conference healthtechnologynet.com